Reference : Vaccinations in patients with immune-mediated inflammatory diseases.
Scientific journals : Article
Human health sciences : Immunology & infectious disease
Human health sciences : Gastroenterology & hepatology
http://hdl.handle.net/2268/71259
Vaccinations in patients with immune-mediated inflammatory diseases.
English
Rahier, Jean-Francois [> > > >]
Moutschen, Michel mailto [Université de Liège - ULg > Département des sciences cliniques > GIGA-R:Immunopath. - Maladies infect. et médec. inter. gén. >]
Van Gompel, Alfons [> > > >]
Van Ranst, Marc [> > > >]
Louis, Edouard mailto [Université de Liège - ULg > Département des sciences cliniques > Hépato-gastroentérologie >]
Segaert, Siegfried [> > > >]
Masson, Pierre [> > > >]
De Keyser, Filip [> > > >]
2010
Rheumatology
Oxford University Press
49
10
1815-27
Yes (verified by ORBi)
International
1462-0324
1462-0332
Oxford
United Kingdom
[en] Patients with immune-mediated inflammatory diseases (IMID) such as RA, IBD or psoriasis, are at increased risk of infection, partially because of the disease itself, but mostly because of treatment with immunomodulatory or immunosuppressive drugs. In spite of their elevated risk for vaccine-preventable disease, vaccination coverage in IMID patients is surprisingly low. This review summarizes current literature data on vaccine safety and efficacy in IMID patients treated with immunosuppressive or immunomodulatory drugs and formulates best-practice recommendations on vaccination in this population. Especially in the current era of biological therapies, including TNF-blocking agents, special consideration should be given to vaccination strategies in IMID patients. Clinical evidence indicates that immunization of IMID patients does not increase clinical or laboratory parameters of disease activity. Live vaccines are contraindicated in immunocompromized individuals, but non-live vaccines can safely be given. Although the reduced quality of the immune response in patients under immunotherapy may have a negative impact on vaccination efficacy in this population, adequate humoral response to vaccination in IMID patients has been demonstrated for hepatitis B, influenza and pneumococcal vaccination. Vaccination status is best checked and updated before the start of immunomodulatory therapy: live vaccines are not contraindicated at that time and inactivated vaccines elicit an optimal immune response in immunocompetent individuals.
http://hdl.handle.net/2268/71259
also: http://hdl.handle.net/2268/83933
10.1093/rheumatology/keq183

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
2010-Vaccinations in patients... inflammatory diseases-Rheumatology-PostPA.pdfAuthor postprint148.58 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.